Publications by authors named "Melanie Nufer"
Donor derived regulatory T lymphocytes and the JAK1/2 kinase inhibitor ruxolitinib are currently being evaluated as therapeutic options in the treatment of chronic graft versus host disease (cGvHD). In this work, we aimed to determine if the combined use of both agents can exert a synergistic effect in the treatment of GvHD. For this purpose, we studied the effect of this combination both in vitro and in a GvHD mouse model.
View Article and Find Full Text PDFArticle Synopsis
- Scientists studied a drug called ixazomib to improve immune responses after people get bone marrow transplants.
- The drug helped mice live longer and reduced the risk of a serious condition called chronic graft-versus-host disease (cGvHD).
- Ixazomib also boosted certain immune cells while keeping important effects against leukemia, making the immune system work better without causing too many problems.